Broad Institute launches the Metastatic Prostate Cancer Project

Last May we had told you about an initiative at the Broad Institute in Cambridge, Massachusetts, designed — initially —  to generate a comprehensive database of advanced prostate cancer treatment results based on the genetics of individual patients and their tumors. … READ MORE …

Astellas, Medivation initiate TRUMPET registry study

Many patients newly diagnosed with castration-resistant prostate cancer (CRPC) may be interested in participating in a new registry study known as the TRUMPET study, which has just started to enroll patients and is sponsored by Astellas and Medivation (the developers and marketers of enzalutamide/Xtandi). … READ MORE …

Focal therapy: time to step up to the plate (or not)!

An opinion piece in the May 4 issue of the Journal of Clinical Oncology has outlined serious (and not unreasonable)  questions about the long-term viability of focal therapy (of any type) as a method for the treatment of small foci of localized prostate cancer. … READ MORE …